Insurance denials of initial attempts to fill brand-name prescription drugs with no generic competitors increased by more than two-thirds from 2018 to 2024, according to a study published online in the ...

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the American Enterprise Institute found that insurance denials of first attempts to fill prescriptions for brand-name prescription drugs with no generic competitors increased more than two-thirds between 2018 and 2024.